The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1732
July 7, 2025
View Complete Issue         Table of Contents 2019 
A Blood Test for Alzheimer's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Blood Test for Alzheimer's Disease
July 7, 2025 (Issue: 1732)
The FDA has cleared the Lumipulse G pTau217/ β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased diagnostic test, for early detection of amyloid plaque pathology associated with Alzheimer's disease (AD) in adults ≥50 years old who are...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Blood Test for Alzheimer's Disease
Article code: 1732b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.